KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Total Non-Current Liabilities (2016 - 2022)

Inovio Pharmaceuticals' Total Non-Current Liabilities history spans 13 years, with the latest figure at $126.2 million for Q4 2022.

  • For Q4 2022, Total Non-Current Liabilities rose 31.08% year-over-year to $126.2 million; the TTM value through Dec 2022 reached $126.2 million, up 31.08%, while the annual FY2022 figure was $126.2 million, 31.08% up from the prior year.
  • Total Non-Current Liabilities for Q4 2022 was $126.2 million at Inovio Pharmaceuticals, up from $124.6 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $161.7 million in Q2 2022 and bottomed at $36.9 million in Q3 2018.
  • The 5-year median for Total Non-Current Liabilities is $93.3 million (2021), against an average of $93.1 million.
  • The largest annual shift saw Total Non-Current Liabilities soared 214.22% in 2019 before it tumbled 43.27% in 2020.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $44.1 million in 2018, then skyrocketed by 214.22% to $138.5 million in 2019, then crashed by 43.27% to $78.6 million in 2020, then rose by 22.51% to $96.3 million in 2021, then skyrocketed by 31.08% to $126.2 million in 2022.
  • Per Business Quant, the three most recent readings for INO's Total Non-Current Liabilities are $126.2 million (Q4 2022), $124.6 million (Q3 2022), and $161.7 million (Q2 2022).